Cite
HARVARD Citation
Watanabe, K. et al. (2022). Efficacy and safety of first-line osimertinib treatment and postprogression patterns of care in patients with epidermal growth factor receptor activating mutation-positive advanced non-small cell lung cancer (Reiwa study): study protocol of a multicentre, real-world observational study. BMJ open. 12 (1), p. . [Online].